-transparent.png){kind=logo}
Studies were conducted to evaluate the efficacy of scopolamine, absorbed through intact skin, in preventing motion sickness at sea. Efficacy of transdermal scopolamine was compared with oral dimenhydrinate and placebo. Transdermal applications were made 4 to 16 hr before exposure to motion. Dimenhydrinate or placebo was given 1.5 hr before motion and again 2.5 hr after motion began. Comparison with placebo indicated that transdermal scopolamine provided protection against motion sickness at a significance level of p = 0.0001 and oral dimenhydrinate at a level of p = 0.05. Dry mouth, drowsiness, and blurred vision associated with transdermal scopolamine therapy were minimal.
N M Price, and
L G Schmitt, and
J McGuire, and
J E Shaw, and
G Trobough
January 1982,
Pharmacotherapy,
N M Price, and
L G Schmitt, and
J McGuire, and
J E Shaw, and
G Trobough
October 1981,
The Medical letter on drugs and therapeutics,
N M Price, and
L G Schmitt, and
J McGuire, and
J E Shaw, and
G Trobough
January 2006,
Clinical pharmacokinetics,
N M Price, and
L G Schmitt, and
J McGuire, and
J E Shaw, and
G Trobough
November 1983,
Aviation, space, and environmental medicine,
N M Price, and
L G Schmitt, and
J McGuire, and
J E Shaw, and
G Trobough
July 1984,
Clinical pharmacology and therapeutics,
N M Price, and
L G Schmitt, and
J McGuire, and
J E Shaw, and
G Trobough
June 1981,
Aviation, space, and environmental medicine,
N M Price, and
L G Schmitt, and
J McGuire, and
J E Shaw, and
G Trobough
October 1982,
Harefuah,
N M Price, and
L G Schmitt, and
J McGuire, and
J E Shaw, and
G Trobough
October 1990,
Zhonghua er bi yan hou ke za zhi,
N M Price, and
L G Schmitt, and
J McGuire, and
J E Shaw, and
G Trobough
July 1992,
Aviation, space, and environmental medicine,
N M Price, and
L G Schmitt, and
J McGuire, and
J E Shaw, and
G Trobough
December 1950,
Toulouse medical,
